Life Cycle Assessment of an Enzymatic Ibuprofen Production Process with Automatic Recycling and Purification

Abstract

In this study, the environmental impacts of three ibuprofen production routes, namely, the BHC, the Bogdan, and the newly developed enzymatic synthetic routes (modified Bogdan process), are assessed and compared by the application of life cycle assessment (LCA). Based on the data obtained through literature and laboratory-based experiments, a pilot-scale production with a capacity of 500 g/day of ibuprofen was simulated to generate inventory data for the LCA study, using Aspen Plus V11. The wellestablished BHC process was chosen as the benchmark to quantify the operational and environmental benefits of the innovative enzymatic Bogdan flow synthetic process. The comparison highlights the benefit of adopting the modified Bogdan synthesis route via an enzymatic catalyst. Results show that a general reduction of environmental impact is achievable across the whole set of impact categories of the analysis, and the magnitude of such reduction depends on the efficiency of recycling in the production system. Considering a 50% efficiency of recycling, the modified Bogdan system achieves lower environmental impacts in some impact categories like Acidification, Ecotoxicity of freshwater, Human toxicity, Particulate matter, and Resource depletion (mineral, fossils, renewables) while having higher impacts on the rest of the impact categories. Yet, the new process proposed here scores better environmental performances in all of the impact categories when the enzyme recycling is close to 100%, which is promising for future technology development.

HealthcareLCA: an open-access living database of health-care environmental impact assessments

“…A 2021 review of surgical equipment concluded that the provision and use of singleuse surgical equipment tends to have a larger environmental impact across a broad range of parameters, including GWP, acidification, eutroph ication, ozone depletion, and smog formation, compared with equivalent reusables. 21 Environmental impacts have been evaluated for a range of pharmaceutical agents, including anaesthetics, [117][118][119][120] anal gesics, 26,117,[121][122][123][124][125] antibiotics, 26,[126][127][128] antiemetics, 117 antide pres sants, 129 bronchodilators, [130][131][132] inhaled corticosteroids, 130,131 medical oxygen, 133 monoclonal antibodies, 134 muscle relax ants and reversal agents, 117 phosphodiesterase inhibitors, 135 sedatives, 117 sympathomimetics, 117 vitamins, 136 and vac cines. 137,138 Impacts were most commonly reported by kilograms of active pharmaceutical ingredient, with wide ranging estimates (2•3 kg CO 2 e for naproxen 26 to 280 000 kg CO 2 e for nivolumab; 134 appendix pp 7-8).…”

Life Cycle Assessment of Hydrotropic Antisolvent Crystallization and Antisolvent Crystallization: A Comparative Study

“…Using life cycle assessment (LCA), processes and products with a quantitative impact can be evaluated. Recent environmental awareness has led to LCA studies being conducted on a variety of products such as food, , chemicals, , coffee, , and pharmaceuticals. , In recent years, many researchers have published articles on LCA of various active pharmaceutical ingredients − and articles related to the comparative life cycle assessment of various chemical compounds. − A scale up framework has also been evaluated using LCA studies. − Sahu et al (2023) have carried out a LCA for the antisolvent crystallization for the selective salt recovery . The LCA study associated with crystallization using SimaPro was reported by De Marco (2022) .…”

Environmental Sustainability of the Globalized Pharmaceutical Supply Chains: The Case of Tenofovir Disoproxil Fumarate

“…Moreover, the environmental sustainability of pharmaceutical products can be affected by many factors, including the selection of heating fuel, packaging specification, supply chain network, disposal method, and optimization of industrial-scale manufacturing processes. Previous work confirmed the effectiveness of improving the environmental sustainability of healthcare and pharmaceutical products through process improvement, product design optimization, and influencing consumer behaviors. − However, there is no systematic environmental assessment in the academic literature on the impacts of the geographical variation in the production, formulation, and prescription of drugs and the variation of choices made by manufacturers, including packaging size and material, heating fuel type, transportation mode, and plant capacity, throughout the drug’s life cycle.…”